Hirayasu Kai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hirayasu Kai has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Kunihiro Yamagata
Division of Preventive and Sports Nephrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba , Ibaraki
6 shared publications Joichi Usui
Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
4 shared publicationsAkihisa Hattori
Department of Nephrology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Japan
3 shared publicationsChie Saito
Department of Nephrology, University of Tsukuba Hospital, Tsukuba, Japan
3 shared publications- Chie Saito
Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan
3 shared publications - Joichi Usui
Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
3 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 65 (6) , 788-794
Efficacy and Safety of Dotinurad in Patients with Advanced Chronic Kidney Disease
Objective Hyperuricemia is associated with cardiovascular disease and chronic kidney disease (CKD). Dotinurad is a new uricosuric drug that has not been evaluated in clinical trials in patients with advanced CKD (CKD G3b-G5). This study evaluated the efficacy of dotinurad in lowering serum uric acid levels, its safety profile, and its effect on the renal function in hyperuricemic patients with CKD G3b to G5. Methods This was a single-center retrospective observational study. Patients and Materials Fourteen patients with CKD G3b to G5 who received dotinurad in the outpatient clinic and for whom data were available for six months before and after treatment were enrolled in this study. Serum uric acid levels six months after treatment and the estimated glomerular filtration rate (eGFR) six months before and after treatment were evaluated. Results Serum uric acid levels significantly decreased from 8.2 (8.0-8.5) mg/dL to 6.2 (5.9-7.2) mg/dL six months after treatment (p<0.01). The eGFR was 25.4 (19.4-40.6) mL/min/1.73 m2 6 months before treatment and 24.9 (18.3-35.5) mL/min/1.73 m2 at the time of treatment, but 24.4 (19.2-36.4) mL/min/1.73 m2 at 6 months after treatment, with no significant change noted. No adverse events were observed. Conclusion Dotinurad can safely lower serum uric acid levels in hyperuricemic patients with advanced CKD.
- 15 March 2026
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 65 (6) , 788-794
Open AccessEfficacy and Safety of Dotinurad in Patients with Advanced Chronic Kidney Disease
Objective Hyperuricemia is associated with cardiovascular disease and chronic kidney disease (CKD). Dotinurad is a new uricosuric drug that has not been evaluated in clinical trials in patients with advanced CKD (CKD G3b-G5). This study evaluated the efficacy of dotinurad in lowering serum uric acid levels, its safety profile, and its effect on the renal function in hyperuricemic patients with CKD G3b to G5. Methods This was a single-center retrospective observational study. Patients and Materials Fourteen patients with CKD G3b to G5 who received dotinurad in the outpatient clinic and for whom data were available for six months before and after treatment were enrolled in this study. Serum uric acid levels six months after treatment and the estimated glomerular filtration rate (eGFR) six months before and after treatment were evaluated. Results Serum uric acid levels significantly decreased from 8.2 (8.0-8.5) mg/dL to 6.2 (5.9-7.2) mg/dL six months after treatment (p<0.01). The eGFR was 25.4 (19.4-40.6) mL/min/1.73 m2 6 months before treatment and 24.9 (18.3-35.5) mL/min/1.73 m2 at the time of treatment, but 24.4 (19.2-36.4) mL/min/1.73 m2 at 6 months after treatment, with no significant change noted. No adverse events were observed. Conclusion Dotinurad can safely lower serum uric acid levels in hyperuricemic patients with advanced CKD.
- Open Access
- 15 July 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (9) , 101059
Renal Prognostic Identification in Patients With Autosomal Dominant Polycystic Kidney Disease by Whole Genome Sequencing: A Prospective, Observational Study
- 15 July 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (9) , 101059
Open AccessRenal Prognostic Identification in Patients With Autosomal Dominant Polycystic Kidney Disease by Whole Genome Sequencing: A Prospective, Observational Study
- Open Access
- 15 July 2025
- Published by Springer Nature in CEN Case Reports
- Vol. 14 (5) , 686
Correction: A case of autosomal dominant polycystic kidney disease with systemic lupus erythematosus developing after SARS‑CoV‑2 vaccination
- 15 July 2025
- Published by Springer Nature in CEN Case Reports
- Vol. 14 (5) , 686
Open AccessCorrection: A case of autosomal dominant polycystic kidney disease with systemic lupus erythematosus developing after SARS‑CoV‑2 vaccination
- Open Access
- 20 May 2025
- Published by Springer Nature in CEN Case Reports
- Vol. 14 (5) , 679-685
A case of autosomal dominant polycystic kidney disease with systemic lupus erythematosus developing after SARS-CoV-2 vaccination
Although SARS-CoV-2 vaccines, particularly mRNA-based formulations, have demonstrated high efficacy and safety, adverse events including autoimmune activity have been reported. We report a case of systemic lupus erythematosus (SLE) following SARS-CoV-2 vaccination in a 52-year-old Japanese female with autosomal dominant polycystic kidney disease (ADPKD). The patient presented with nephrotic syndrome and severe thrombocytopenia and fulfilled the following four criteria for SLE classification: positive antinuclear antibodies, positive anti-ds-DNA antibodies, renal involvement, and reductions in two blood cell lines (leukopenia and thrombocytopenia). The patient responded favorably to prednisolone therapy, although hydroxychloroquine was avoided because of a suspected allergic predisposition. This case underscores the potential for exogenous triggers such as vaccination to induce SLE, highlighting the need for vigilance in managing autoimmune responses, particularly in patients with chronic conditions such as ADPKD. Despite the patient’s history of ADPKD, no previous reports have linked this condition to post-vaccine SLE. Concurrent nephrotic syndrome in patients with ADPKD is rare, and the possibility of other treatable glomerular diseases should be considered when this is seen.
- 20 May 2025
- Published by Springer Nature in CEN Case Reports
- Vol. 14 (5) , 679-685
Open AccessA case of autosomal dominant polycystic kidney disease with systemic lupus erythematosus developing after SARS-CoV-2 vaccination
Although SARS-CoV-2 vaccines, particularly mRNA-based formulations, have demonstrated high efficacy and safety, adverse events including autoimmune activity have been reported. We report a case of systemic lupus erythematosus (SLE) following SARS-CoV-2 vaccination in a 52-year-old Japanese female with autosomal dominant polycystic kidney disease (ADPKD). The patient presented with nephrotic syndrome and severe thrombocytopenia and fulfilled the following four criteria for SLE classification: positive antinuclear antibodies, positive anti-ds-DNA antibodies, renal involvement, and reductions in two blood cell lines (leukopenia and thrombocytopenia). The patient responded favorably to prednisolone therapy, although hydroxychloroquine was avoided because of a suspected allergic predisposition. This case underscores the potential for exogenous triggers such as vaccination to induce SLE, highlighting the need for vigilance in managing autoimmune responses, particularly in patients with chronic conditions such as ADPKD. Despite the patient’s history of ADPKD, no previous reports have linked this condition to post-vaccine SLE. Concurrent nephrotic syndrome in patients with ADPKD is rare, and the possibility of other treatable glomerular diseases should be considered when this is seen.
- Open Access
- 21 March 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (5) , 724-731
Renal Hemodynamic and Functional Changes in Patients with ADPKD
Key Points: The mechanism of decreased renal function in autosomal dominant polycystic kidney disease has not been elucidated yet. The presented data highlight specific renal hemodynamic changes that occur in patients with autosomal dominant polycystic kidney disease. Background: Although the mechanisms underlying cyst enlargement in autosomal dominant polycystic kidney disease (ADPKD) are becoming clearer, those of renal dysfunction are not fully understood. In particular, total kidney volume and renal function do not always correspond. To elucidate this discrepancy, we studied in detail glomerular hemodynamic changes during ADPKD progression. Methods: Sixty-one patients with ADPKD with baseline height-adjusted total kidney volume (Ht-TKV) of 933±537 ml/m and serum creatinine of 1.16±0.62 mg/dl were followed for 2 years. GFR and renal plasma flow (RPF) slopes were calculated from inulin clearance (Cin) and para-aminohippuric acid clearance (CPAH), respectively, while glomerular hydrostatic pressure (Pglo), afferent resistance (RA), and efferent resistance (RE) were estimated using the Gomez formulas. Each parameter was compared with baseline Ht-TKV. Patients were also subclassified into 1A–1B and 1C–1E groups according to the baseline Mayo imaging classification and then compared with respect to GFR, RPF, filtration fraction, and glomerular hemodynamics. Results: After 2 years, Ht-TKV increased (933±537 to 1000±648 ml/m, P < 0.01), GFR decreased (66.7±30 to 57.3±30.1 ml/min per 1.73 m2, P < 0.001), and RPF decreased (390±215 to 339±190 ml/min per 1.73 m2, P < 0.05). Furthermore, Pglo was decreased and RA was increased. Baseline Ht-TKV was inversely correlated with GFR (r=−0.29, P < 0.05), but there was no association between baseline Ht-TKV and RPF, Pglo, RA, or RE annual changes. However, despite an increase in RE in the 1A–1B group, RE was decreased in the 1C–1E group. As a result, RE slope was significantly lower in the 1C–1E group than the 1A–1B group over time (−83 [−309 to 102] to 164 [−34 to 343] dyne·s·cm−5, P < 0.01). Conclusions: This is the first report examining yearly changes of GFR (inulin), RPF (para-aminohippuric), and renal microcirculation parameters in patients with ADPKD. Our results demonstrate that GFR reduction was caused by RA increase, which was faster because of RE decrease in patients with faster Ht-TKV increase.
- 21 March 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (5) , 724-731
Open AccessRenal Hemodynamic and Functional Changes in Patients with ADPKD
Key Points: The mechanism of decreased renal function in autosomal dominant polycystic kidney disease has not been elucidated yet. The presented data highlight specific renal hemodynamic changes that occur in patients with autosomal dominant polycystic kidney disease. Background: Although the mechanisms underlying cyst enlargement in autosomal dominant polycystic kidney disease (ADPKD) are becoming clearer, those of renal dysfunction are not fully understood. In particular, total kidney volume and renal function do not always correspond. To elucidate this discrepancy, we studied in detail glomerular hemodynamic changes during ADPKD progression. Methods: Sixty-one patients with ADPKD with baseline height-adjusted total kidney volume (Ht-TKV) of 933±537 ml/m and serum creatinine of 1.16±0.62 mg/dl were followed for 2 years. GFR and renal plasma flow (RPF) slopes were calculated from inulin clearance (Cin) and para-aminohippuric acid clearance (CPAH), respectively, while glomerular hydrostatic pressure (Pglo), afferent resistance (RA), and efferent resistance (RE) were estimated using the Gomez formulas. Each parameter was compared with baseline Ht-TKV. Patients were also subclassified into 1A–1B and 1C–1E groups according to the baseline Mayo imaging classification and then compared with respect to GFR, RPF, filtration fraction, and glomerular hemodynamics. Results: After 2 years, Ht-TKV increased (933±537 to 1000±648 ml/m, P < 0.01), GFR decreased (66.7±30 to 57.3±30.1 ml/min per 1.73 m2, P < 0.001), and RPF decreased (390±215 to 339±190 ml/min per 1.73 m2, P < 0.05). Furthermore, Pglo was decreased and RA was increased. Baseline Ht-TKV was inversely correlated with GFR (r=−0.29, P < 0.05), but there was no association between baseline Ht-TKV and RPF, Pglo, RA, or RE annual changes. However, despite an increase in RE in the 1A–1B group, RE was decreased in the 1C–1E group. As a result, RE slope was significantly lower in the 1C–1E group than the 1A–1B group over time (−83 [−309 to 102] to 164 [−34 to 343] dyne·s·cm−5, P < 0.01). Conclusions: This is the first report examining yearly changes of GFR (inulin), RPF (para-aminohippuric), and renal microcirculation parameters in patients with ADPKD. Our results demonstrate that GFR reduction was caused by RA increase, which was faster because of RE decrease in patients with faster Ht-TKV increase.
- Open Access
- 3 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6528
Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in which family history is unclear, a differential diagnosis between ADPKD and other cystic kidney diseases is important. When diagnosing ADPKD, cystic kidney diseases that can easily be excluded using clinical information include: multiple simple renal cysts, acquired cystic kidney disease (ACKD), multilocular renal cyst/multilocular cystic nephroma/polycystic nephroma, multicystic kidney/multicystic dysplastic kidney (MCDK), and unilateral renal cystic disease (URCD). However, there are other cystic kidney diseases that usually require genetic testing, or another means of supplementing clinical information to enable a differential diagnosis of ADPKD. These include autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant tubulointerstitial kidney disease (ADTKD), nephronophthisis (NPH), oral-facial-digital (OFD) syndrome type 1, and neoplastic cystic kidney disease, such as tuberous sclerosis (TSC) and Von Hippel-Lindau (VHL) syndrome. To help physicians evaluate cystic kidney diseases, this article provides a review of cystic kidney diseases for which a differential diagnosis is required for ADPKD.
- 3 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6528
Open AccessCystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in which family history is unclear, a differential diagnosis between ADPKD and other cystic kidney diseases is important. When diagnosing ADPKD, cystic kidney diseases that can easily be excluded using clinical information include: multiple simple renal cysts, acquired cystic kidney disease (ACKD), multilocular renal cyst/multilocular cystic nephroma/polycystic nephroma, multicystic kidney/multicystic dysplastic kidney (MCDK), and unilateral renal cystic disease (URCD). However, there are other cystic kidney diseases that usually require genetic testing, or another means of supplementing clinical information to enable a differential diagnosis of ADPKD. These include autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant tubulointerstitial kidney disease (ADTKD), nephronophthisis (NPH), oral-facial-digital (OFD) syndrome type 1, and neoplastic cystic kidney disease, such as tuberous sclerosis (TSC) and Von Hippel-Lindau (VHL) syndrome. To help physicians evaluate cystic kidney diseases, this article provides a review of cystic kidney diseases for which a differential diagnosis is required for ADPKD.
- Open Access
- 1 March 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (5) , 765-770
Anti-glomerular Basement Membrane Glomerulonephritis During the First Trimester of Pregnancy
A 28-year-old woman was admitted during the eighth week of her pregnancy because her clinical course was consistent with rapid progressive glomerulonephritis (RPGN). Anti-glomerular basement membrane antibody (anti-GBM Ab) and MPO-ANCA were positive, and the anti-GBM Ab titer being extremely high. She was treated with hemodialysis, plasma exchange and prednisolone. She survived the illness; however, neither the fetus nor her kidney function could be rescued. She had HLA-DRB1*1502:01, which differs from the DRB1*1501 associated with anti-GBM GN. When patients have particular symptoms, we should check the urine and serum creatinine to exclude RPGN, even in cases of pregnancy.
- 1 March 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (5) , 765-770
Open AccessAnti-glomerular Basement Membrane Glomerulonephritis During the First Trimester of Pregnancy
A 28-year-old woman was admitted during the eighth week of her pregnancy because her clinical course was consistent with rapid progressive glomerulonephritis (RPGN). Anti-glomerular basement membrane antibody (anti-GBM Ab) and MPO-ANCA were positive, and the anti-GBM Ab titer being extremely high. She was treated with hemodialysis, plasma exchange and prednisolone. She survived the illness; however, neither the fetus nor her kidney function could be rescued. She had HLA-DRB1*1502:01, which differs from the DRB1*1501 associated with anti-GBM GN. When patients have particular symptoms, we should check the urine and serum creatinine to exclude RPGN, even in cases of pregnancy.
- Open Access
- 17 November 2015
- Published by Springer Nature in CEN Case Reports
- Vol. 5 (1) , 87-90
Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan
We report here two cases of autosomal dominant polycystic kidney disease (ADPKD) with renal dysfunction that were treated with tolvaptan. Case 1 was a 47-year-old man with a glomerular filtration rate (GFR) of 17.0 ml/min/1.73 m2 who received tolvaptan treatment (30 mg/day). After treatment, kidney pain was alleviated, and the estimated GFR (eGFR) decline improved from −9.84 ml/min/1.73 m2 per year to −4.08 ml/min/1.73 m2 per year, respectively. The rate of increase in total kidney volume was reduced from 18 % per year before treatment to 4 % per year following tolvaptan administration. Case 2 was a 44-year-old man with a GFR of 22.6 ml/min/1.73 m2, and the eGFR decline improved from −5.76 ml/min/1.73 m2 per year before treatment to −3.12 ml/min/1.73 m2 per year following tolvaptan treatment (30 mg/day). The rate of increase in total kidney volume was also decreased from 10 % per year before treatment to −7 % per year following tolvaptan administration. These results suggested that tolvaptan may be effective in impeding kidney function aggravation and kidney volume increase in ADPKD patients with advanced renal dysfunction.
- 17 November 2015
- Published by Springer Nature in CEN Case Reports
- Vol. 5 (1) , 87-90
Open AccessTwo autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan
We report here two cases of autosomal dominant polycystic kidney disease (ADPKD) with renal dysfunction that were treated with tolvaptan. Case 1 was a 47-year-old man with a glomerular filtration rate (GFR) of 17.0 ml/min/1.73 m2 who received tolvaptan treatment (30 mg/day). After treatment, kidney pain was alleviated, and the estimated GFR (eGFR) decline improved from −9.84 ml/min/1.73 m2 per year to −4.08 ml/min/1.73 m2 per year, respectively. The rate of increase in total kidney volume was reduced from 18 % per year before treatment to 4 % per year following tolvaptan administration. Case 2 was a 44-year-old man with a GFR of 22.6 ml/min/1.73 m2, and the eGFR decline improved from −5.76 ml/min/1.73 m2 per year before treatment to −3.12 ml/min/1.73 m2 per year following tolvaptan treatment (30 mg/day). The rate of increase in total kidney volume was also decreased from 10 % per year before treatment to −7 % per year following tolvaptan administration. These results suggested that tolvaptan may be effective in impeding kidney function aggravation and kidney volume increase in ADPKD patients with advanced renal dysfunction.
- 1 April 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (2) , 174-178
Secondary membranous glomerulonephritis associated with recipient residual lymphoma cells after allogeneic bone marrow transplantation
A 29-year-old man with malignant lymphoma developed membranous nephropathy (MN) after allogeneic bone-marrow transplantation (BMT). There had been no obvious findings of graft versus host diseases (GVHD) after BMT, and the dosage of immunosuppressant drugs had not been reduced during this period. At the onset of MN, a few lymphoma cells still remained in the bone marrow; the patient achieved complete remission of MN after the disappearance of the lymphoma cells. In this case it is suggested that immune complexes including antigens expressed by lymphoma cells might induce MN. Therefore, this is a significant case that may reveal an alternative mechanism of the onset of MN related to BMT.
- 1 April 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (2) , 174-178
Secondary membranous glomerulonephritis associated with recipient residual lymphoma cells after allogeneic bone marrow transplantation
A 29-year-old man with malignant lymphoma developed membranous nephropathy (MN) after allogeneic bone-marrow transplantation (BMT). There had been no obvious findings of graft versus host diseases (GVHD) after BMT, and the dosage of immunosuppressant drugs had not been reduced during this period. At the onset of MN, a few lymphoma cells still remained in the bone marrow; the patient achieved complete remission of MN after the disappearance of the lymphoma cells. In this case it is suggested that immune complexes including antigens expressed by lymphoma cells might induce MN. Therefore, this is a significant case that may reveal an alternative mechanism of the onset of MN related to BMT.